Abeona Therapeutics Inc. (ABEO) Stock Grade

About Abeona Therapeutics Inc.'s fundamentals

Abeona Therapeutics is a small-cap biotechnology company with a market capitalization of $279.1 million that exhibits unusual financial metrics characteristic of early-stage biotech firms. The company's extraordinarily high net margin of 1223.1% and return on equity of 44.7% suggest minimal operating losses relative to a small equity base, though revenue growth has remained flat year-over-year at 0.0%. With a low P/E ratio of 3.9 and no dividend payments, the company appears to be in a pre-profitability or early commercialization phase focused on reinvesting capital into operations rather than returning cash to shareholders.